Industry Research Reports

Home > Reports > Medical Care > Myeloproliferative Disorders Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Myeloproliferative Disorders Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published Date: 2024-01-24

Pages: 89 Pages

Report ld: 2336997

Request Sample

Customized Report

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Myeloproliferative Disorders Drugs Market Size(US$)

CAGR 2024-2030

2.6%

Market Size,2030

USD 7,581.8

Million

Market Snapshot

Market Size in 2024 (Value)

US$ 6,499.7 million

Market Forecast in 2030(Value)

US$ 7,581.8 million

CAGR

2.6%

Years Considered

2019-2030

Base Year

2024

Forecast Period

2024-2030

Source: Secondary research, interviews with experts, and QYResearch analysis

hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.

The global market for Myeloproliferative Disorders Drugs was estimated to be worth US$ 6392.1 million in 2023 and is forecast to a readjusted size of US$ 7581.8 million by 2030 with a CAGR of 2.6% during the forecast period 2024-2030

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

MARKET SEGMENTATION

By Company

Celgene
Bristol-Myers Squibb
Gamida Cell
Incyte
Geron
Promedior
Johnson and Johnson

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

Ph+ CML
Ph- MPN

Segment by Application

Hospitals
Pharmacy

biaoTi REPORT SCOPE

This report aims to provide a comprehensive presentation of the global market for Myeloproliferative Disorders Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Myeloproliferative Disorders Drugs by region & country, by Type, and by Application.

The Myeloproliferative Disorders Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myeloproliferative Disorders Drugs.

biaoTi CHAPTER OUTLINE

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Myeloproliferative Disorders Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Myeloproliferative Disorders Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Myeloproliferative Disorders Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

biaoTi QYRESEARCH'S STRENGTHS

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

TABLE OF CONTENTS

1 Market Overview

1.1 Myeloproliferative Disorders Drugs Product Introduction

1.2 Global Myeloproliferative Disorders Drugs Market Size Forecast

1.3 Myeloproliferative Disorders Drugs Market Trends & Drivers

1.3.1 Myeloproliferative Disorders Drugs Industry Trends

1.3.2 Myeloproliferative Disorders Drugs Market Drivers & Opportunity

1.3.3 Myeloproliferative Disorders Drugs Market Challenges

1.3.4 Myeloproliferative Disorders Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Myeloproliferative Disorders Drugs Players Revenue Ranking (2023)

2.2 Global Myeloproliferative Disorders Drugs Revenue by Company (2019-2024)

2.3 Key Companies Myeloproliferative Disorders Drugs Manufacturing Base Distribution and Headquarters

2.4 Key Companies Myeloproliferative Disorders Drugs Product Offered

2.5 Key Companies Time to Begin Mass Production of Myeloproliferative Disorders Drugs

2.6 Myeloproliferative Disorders Drugs Market Competitive Analysis

2.6.1 Myeloproliferative Disorders Drugs Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Myeloproliferative Disorders Drugs Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myeloproliferative Disorders Drugs as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Ph+ CML

3.1.2 Ph- MPN

3.2 Global Myeloproliferative Disorders Drugs Sales Value by Type

3.2.1 Global Myeloproliferative Disorders Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Myeloproliferative Disorders Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Myeloproliferative Disorders Drugs Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospitals

4.1.2 Pharmacy

4.2 Global Myeloproliferative Disorders Drugs Sales Value by Application

4.2.1 Global Myeloproliferative Disorders Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Myeloproliferative Disorders Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Myeloproliferative Disorders Drugs Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Myeloproliferative Disorders Drugs Sales Value by Region

5.1.1 Global Myeloproliferative Disorders Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Myeloproliferative Disorders Drugs Sales Value by Region (2019-2024)

5.1.3 Global Myeloproliferative Disorders Drugs Sales Value by Region (2025-2030)

5.1.4 Global Myeloproliferative Disorders Drugs Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Myeloproliferative Disorders Drugs Sales Value, 2019-2030

5.2.2 North America Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Myeloproliferative Disorders Drugs Sales Value, 2019-2030

5.3.2 Europe Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Myeloproliferative Disorders Drugs Sales Value, 2019-2030

5.4.2 Asia Pacific Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Myeloproliferative Disorders Drugs Sales Value, 2019-2030

5.5.2 South America Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Myeloproliferative Disorders Drugs Sales Value, 2019-2030

5.6.2 Middle East & Africa Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Myeloproliferative Disorders Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Myeloproliferative Disorders Drugs Sales Value

6.3 United States

6.3.1 United States Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.3.2 United States Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.4.2 Europe Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.5.2 China Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.6.2 Japan Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.7.2 South Korea Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Myeloproliferative Disorders Drugs Sales Value, 2019-2030

6.9.2 India Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Myeloproliferative Disorders Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Celgene

7.1.1 Celgene Profile

7.1.2 Celgene Main Business

7.1.3 Celgene Myeloproliferative Disorders Drugs Products, Services and Solutions

7.1.4 Celgene Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.1.5 Celgene Recent Developments

7.2 Bristol-Myers Squibb

7.2.1 Bristol-Myers Squibb Profile

7.2.2 Bristol-Myers Squibb Main Business

7.2.3 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Products, Services and Solutions

7.2.4 Bristol-Myers Squibb Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.2.5 Bristol-Myers Squibb Recent Developments

7.3 Gamida Cell

7.3.1 Gamida Cell Profile

7.3.2 Gamida Cell Main Business

7.3.3 Gamida Cell Myeloproliferative Disorders Drugs Products, Services and Solutions

7.3.4 Gamida Cell Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.3.5 Incyte Recent Developments

7.4 Incyte

7.4.1 Incyte Profile

7.4.2 Incyte Main Business

7.4.3 Incyte Myeloproliferative Disorders Drugs Products, Services and Solutions

7.4.4 Incyte Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.4.5 Incyte Recent Developments

7.5 Geron

7.5.1 Geron Profile

7.5.2 Geron Main Business

7.5.3 Geron Myeloproliferative Disorders Drugs Products, Services and Solutions

7.5.4 Geron Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.5.5 Geron Recent Developments

7.6 Promedior

7.6.1 Promedior Profile

7.6.2 Promedior Main Business

7.6.3 Promedior Myeloproliferative Disorders Drugs Products, Services and Solutions

7.6.4 Promedior Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.6.5 Promedior Recent Developments

7.7 Johnson and Johnson

7.7.1 Johnson and Johnson Profile

7.7.2 Johnson and Johnson Main Business

7.7.3 Johnson and Johnson Myeloproliferative Disorders Drugs Products, Services and Solutions

7.7.4 Johnson and Johnson Myeloproliferative Disorders Drugs Revenue (US$ Million) & (2019-2024)

7.7.5 Johnson and Johnson Recent Developments

8 Industry Chain Analysis

8.1 Myeloproliferative Disorders Drugs Industrial Chain

8.2 Myeloproliferative Disorders Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Myeloproliferative Disorders Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Myeloproliferative Disorders Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

TABLE OF FIGURES

List of Tables

Table 1. Myeloproliferative Disorders Drugs Market Trends

Table 2. Myeloproliferative Disorders Drugs Market Drivers & Opportunity

Table 3. Myeloproliferative Disorders Drugs Market Challenges

Table 4. Myeloproliferative Disorders Drugs Market Restraints

Table 5. Global Myeloproliferative Disorders Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Myeloproliferative Disorders Drugs Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Myeloproliferative Disorders Drugs Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Myeloproliferative Disorders Drugs Product Type

Table 9. Key Companies Time to Begin Mass Production of Myeloproliferative Disorders Drugs

Table 10. Global Myeloproliferative Disorders Drugs Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myeloproliferative Disorders Drugs as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Myeloproliferative Disorders Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Myeloproliferative Disorders Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Myeloproliferative Disorders Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Myeloproliferative Disorders Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Myeloproliferative Disorders Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Myeloproliferative Disorders Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Myeloproliferative Disorders Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Myeloproliferative Disorders Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Myeloproliferative Disorders Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Myeloproliferative Disorders Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Myeloproliferative Disorders Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Myeloproliferative Disorders Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Myeloproliferative Disorders Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Myeloproliferative Disorders Drugs Sales Value by Region (2019-2024) & (%)

Table 27. Global Myeloproliferative Disorders Drugs Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Myeloproliferative Disorders Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Myeloproliferative Disorders Drugs Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Myeloproliferative Disorders Drugs Sales Value, (2025-2030) & (US$ Million)

Table 31. Celgene Basic Information List

Table 32. Celgene Description and Business Overview

Table 33. Celgene Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 34. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Celgene (2019-2024)

Table 35. Celgene Recent Developments

Table 36. Bristol-Myers Squibb Basic Information List

Table 37. Bristol-Myers Squibb Description and Business Overview

Table 38. Bristol-Myers Squibb Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 39. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Bristol-Myers Squibb (2019-2024)

Table 40. Bristol-Myers Squibb Recent Developments

Table 41. Gamida Cell Basic Information List

Table 42. Gamida Cell Description and Business Overview

Table 43. Gamida Cell Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 44. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Gamida Cell (2019-2024)

Table 45. Gamida Cell Recent Developments

Table 46. Incyte Basic Information List

Table 47. Incyte Description and Business Overview

Table 48. Incyte Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 49. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Incyte (2019-2024)

Table 50. Incyte Recent Developments

Table 51. Geron Basic Information List

Table 52. Geron Description and Business Overview

Table 53. Geron Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 54. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Geron (2019-2024)

Table 55. Geron Recent Developments

Table 56. Promedior Basic Information List

Table 57. Promedior Description and Business Overview

Table 58. Promedior Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 59. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Promedior (2019-2024)

Table 60. Promedior Recent Developments

Table 61. Johnson and Johnson Basic Information List

Table 62. Johnson and Johnson Description and Business Overview

Table 63. Johnson and Johnson Myeloproliferative Disorders Drugs Products, Services and Solutions

Table 64. Revenue (US$ Million) in Myeloproliferative Disorders Drugs Business of Johnson and Johnson (2019-2024)

Table 65. Johnson and Johnson Recent Developments

Table 66. Key Raw Materials Lists

Table 67. Raw Materials Key Suppliers Lists

Table 68. Myeloproliferative Disorders Drugs Downstream Customers

Table 69. Myeloproliferative Disorders Drugs Distributors List

Table 70. Research Programs/Design for This Report

Table 71. Key Data Information from Secondary Sources

Table 72. Key Data Information from Primary Sources

Table 73. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Myeloproliferative Disorders Drugs Product Picture

Figure 2. Global Myeloproliferative Disorders Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Myeloproliferative Disorders Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Myeloproliferative Disorders Drugs Report Years Considered

Figure 5. Global Myeloproliferative Disorders Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Myeloproliferative Disorders Drugs Revenue in 2023

Figure 7. Myeloproliferative Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Ph+ CML Picture

Figure 9. Ph- MPN Picture

Figure 10. Global Myeloproliferative Disorders Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Myeloproliferative Disorders Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospitals

Figure 13. Product Picture of Pharmacy

Figure 14. Global Myeloproliferative Disorders Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Myeloproliferative Disorders Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 16. North America Myeloproliferative Disorders Drugs Sales Value (2019-2030) & (US$ Million)

Figure 17. North America Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

Figure 18. Europe Myeloproliferative Disorders Drugs Sales Value (2019-2030) & (US$ Million)

Figure 19. Europe Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

Figure 20. Asia Pacific Myeloproliferative Disorders Drugs Sales Value (2019-2030) & (US$ Million)

Figure 21. Asia Pacific Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

Figure 22. South America Myeloproliferative Disorders Drugs Sales Value (2019-2030) & (US$ Million)

Figure 23. South America Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

Figure 24. Middle East & Africa Myeloproliferative Disorders Drugs Sales Value (2019-2030) & (US$ Million)

Figure 25. Middle East & Africa Myeloproliferative Disorders Drugs Sales Value by Country (%), 2023 VS 2030

Figure 26. Key Countries/Regions Myeloproliferative Disorders Drugs Sales Value (%), (2019-2030)

Figure 27. United States Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 28. United States Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 29. United States Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 30. Europe Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 31. Europe Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 32. Europe Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 33. China Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 34. China Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 35. China Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 36. Japan Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 37. Japan Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 38. Japan Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 39. South Korea Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 40. South Korea Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 41. South Korea Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 42. Southeast Asia Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 43. Southeast Asia Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 44. Southeast Asia Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 45. India Myeloproliferative Disorders Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 46. India Myeloproliferative Disorders Drugs Sales Value by Type (%), 2023 VS 2030

Figure 47. India Myeloproliferative Disorders Drugs Sales Value by Application (%), 2023 VS 2030

Figure 48. Myeloproliferative Disorders Drugs Industrial Chain

Figure 49. Myeloproliferative Disorders Drugs Manufacturing Cost Structure

Figure 50. Channels of Distribution (Direct Sales, and Distribution)

Figure 51. Bottom-up and Top-down Approaches for This Report

Figure 52. Data Triangulation

KEY QUESTIONS ADDRESSED BY THE REPORT

Which companies rank high in the global Myeloproliferative Disorders Drugs market? zhanKai

The top companies in the global Myeloproliferative Disorders Drugs market are Celgene、Bristol-Myers Squibb、Gamida Cell.

What was the global market size of Myeloproliferative Disorders Drugs in 2030? shouQi

Which region is expected to have the highest market share? shouQi

What is the annual compound growth rate of the global Myeloproliferative Disorders Drugs market size from 2024 to 2030? shouQi

What was the global market size of Myeloproliferative Disorders Drugs in 2024? shouQi

Related Reports

Myeloproliferative Disorders Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Myeloproliferative Disorders Drugs was estimated to be worth US$ 6807 million in 2025 and is projected to reach US$ 8127 million, growing at a CAGR of 2.6% from 2026 to 2032.
Published Date: 2026-07-14
Pages: 103
USD 3950.00
(Single User License)
Global Myeloproliferative Disorders Drugs Market Research Report 2026
The global Myeloproliferative Disorders Drugs market was valued at US$ 6807 million in 2025 and is anticipated to reach US$ 8127 million by 2032, at a CAGR of 2.6% from 2026 to 2032.
Published Date: 2026-04-27
Pages: 102
USD 2900.00
(Single User License)
Global Myeloproliferative Disorders Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Myeloproliferative Disorders Drugs market size was US$ 6652 million in 2024 and is forecast to a readjusted size of US$ 7941 million by 2031 with a CAGR of 2.6% during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 80
USD 4250.00
(Single User License)
Myeloproliferative Disorders Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Myeloproliferative Disorders Drugs was estimated to be worth US$ 6652 million in 2024 and is forecast to a readjusted size of US$ 7941 million by 2031 with a CAGR of 2.6% during the forecast period 2025-2031.
Published Date: 2025-02-27
Pages: 88
USD 3950.00
(Single User License)
Global Myeloproliferative Disorders Drugs Market Research Report 2025
The global market for Myeloproliferative Disorders Drugs was valued at US$ 6652 million in the year 2024 and is projected to reach a revised size of US$ 7941 million by 2031, growing at a CAGR of 2.6% during the forecast period.
Published Date: 2025-02-27
Pages: 80
USD 2900.00
(Single User License)
Global Myeloproliferative Disorders Drugs Market Insights, Forecast to 2030
hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
Published Date: 2024-04-28
Pages: 90
USD 4900.00
(Single User License)
Global Myeloproliferative Disorders Drugs Market Research Report 2024
hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
Published Date: 2024-01-04
Pages: 77
USD 2900.00
(Single User License)

Myeloproliferative Disorders Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Myeloproliferative Disorders Drugs was estimated to be worth US$ 6807 million in 2025 and is projected to reach US$ 8127 million, growing at a CAGR of 2.6% from 2026 to 2032.
Published: 2026-07-14
Pages: 103
USD 3950.00 (Single User License)
Global Myeloproliferative Disorders Drugs Market Research Report 2026
The global Myeloproliferative Disorders Drugs market was valued at US$ 6807 million in 2025 and is anticipated to reach US$ 8127 million by 2032, at a CAGR of 2.6% from 2026 to 2032.
Published: 2026-04-27
Pages: 102
USD 2900.00 (Single User License)
Global Myeloproliferative Disorders Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Myeloproliferative Disorders Drugs market size was US$ 6652 million in 2024 and is forecast to a readjusted size of US$ 7941 million by 2031 with a CAGR of 2.6% during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 80
USD 4250.00 (Single User License)
Myeloproliferative Disorders Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Myeloproliferative Disorders Drugs was estimated to be worth US$ 6652 million in 2024 and is forecast to a readjusted size of US$ 7941 million by 2031 with a CAGR of 2.6% during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 88
USD 3950.00 (Single User License)
Global Myeloproliferative Disorders Drugs Market Research Report 2025
The global market for Myeloproliferative Disorders Drugs was valued at US$ 6652 million in the year 2024 and is projected to reach a revised size of US$ 7941 million by 2031, growing at a CAGR of 2.6% during the forecast period.
Published: 2025-02-27
Pages: 80
USD 2900.00 (Single User License)
Global Myeloproliferative Disorders Drugs Market Insights, Forecast to 2030
hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
Published: 2024-04-28
Pages: 90
USD 4900.00 (Single User License)
Global Myeloproliferative Disorders Drugs Market Research Report 2024
hronic myeloproliferative disorders are rare hematological malignances that involve abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow.
Published: 2024-01-04
Pages: 77
USD 2900.00 (Single User License)